

## Chang Tumor Targeting Nanodelivery Systems: Partial List

1/27/05

[change@georgetown.edu](mailto:change@georgetown.edu)

1. Xu, L., Pirollo, K.F., and Chang, E.H. Transferrin-Liposome-Mediated p53 Sensitization of Squamous Cell Carcinoma of the Head and neck to Radiation *In Vitro*. *Human Gene Therapy*, 8: 467-475 1997.
2. Xu, L., Pirollo, K.F., Rait, A., Murray, A.L. and Chang, E.H. Systemic p53 Gene Therapy In Combination with Radiation Results in Human Tumor Regression. *Tumor Targeting*, 4: 92-114 1999.
3. Xu, L., Pirollo, K.F., Rait, A. and Chang, E.H. Transferrin-Liposome-Mediated Systemic p53 Gene Therapy in Combination with Radiation Results in Regression of Human Head + Neck Cancer Xenografts. *Human Gene Therapy*, 10: 2941-2952 1999.
4. Rait, A., Krygier, J.E., Pirollo, K.F. and Chang, E.H. Sensitization of Breast Cancer Cells to Taxol by Antisense HER-2 Oligonucleotides. *Antisense & Nuc. Acid Drug Dev.*, 9: 403-408 1999.
5. Chang, E.H., Pirollo, K.F. and Bouker, K.B. p53 Gene Therapy: Key to Modulating Resistance to Anti-Cancer Therapies. *Molecular Medicine Today*, 6: 358-364 2000.
6. Rait, A., Rait, V., Pirollo, K.F., Kryger, J. and Chang, E.H. Inhibitory Effects of the Combination of HER-2/erbB-2 AS Oligo and Chemotherapeutic Agents Used for Treatment of Human Breast Cancer Cells. *Cancer Gene Therapy* 8: 728-739 2001.
7. Xu, L., Tang, W.H., Huang, C.C., Alexander, W., Xiang, L.M., Pirollo, K.F., Rait, A., and Chang, E.H. Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv. *Molecular Medicine* 7: 723-734 2001
8. Xu, L., Frederick, P., Pirollo, K., Tang, W., Rait, A., Xiang, L., Huang, W., Cruz, I., Yin, Y., Chang, E.H. Self-assembled Virus-mimicking Nanostructure for High Efficiency Tumor-targeted Gene Delivery. *Human Gene Therapy* 13: 469-481 2002.
9. Xu, L., Huang, C.C., Huang, W.Q., Rait, A., Yin, Y.Z., Cruz, M., Xiang, L., Pirollo, K.F., and Chang, E.H.. Systemic Tumor-Targeted Gene Delivery by Anti-Transferrin Receptor scFv-Immunoliposomes. *Molecular Cancer Therapeutics* 1: 337-346 2002
10. Rait, A., Pirollo, K.F., Xiang, L.M., Ulick, D. and Chang, E.H.. Tumor-Targeting, Systemically Delivered Antisense HER-2 Chemosensitizes Human Breast Cancer Xenografts Irrespective of HER-2 Levels. *Molecular Medicine* 8(8); 476-487 2002.
11. Pirollo, K.F., Xu, L. and Chang, E.H. Immunoliposomes: A Targeted Delivery Tool for Cancer Treatment in Vector Targeting for Therapeutic Gene Delivery. (D.T. Curiel and J.T. Douglas, eds.) John Wiley & Sons. 33-62 2002
12. Pirollo, K.F., Rait, A., Sleer, L. and Chang, E.H. Antisense Therapeutics: From Theory to Clinical Practice. *Pharmacology and Therapeutics* 99: 55-77 2003.
13. Rait, A., Pirollo, K.F., Ulick, D., Cullen, K., and Chang, E.H. HER-2-Targeted Antisense Oligonucleotides Result in Sensitization of Head and Neck Cancer Cells to Chemotherapeutic Agents. *Ann. N.Y. Acad. Sci.* 1002: 1-12 2003
14. Yu, W., Yu, B., Pirollo, K.F., Zhou, Q., Rait, A., Xiang, L., Ertem, E., and Chang, E.H. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. *Nucleic Acids Research*, 32(5): e48. 2004
15. Yu, W., Pirollo, K.F., Rait, A., Yu, B., Xiang, L.M., Huang, W.Q., Zhou, Q., Ertem, G., and Chang, E.H. A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene. *Gene Therapy* 11: 1434-1440 2004.
16. Jhaveri, MS., Rait, A., Chung, K-M, Trepel, JB., Chang, EH. Antisense Oligonucleotides Targeted to Human Alpha Folate Receptor Inhibit Breast Cancer Cell Growth and Sensitize the Cells to Doxorubicin Treatment. *Molecular Cancer Therapeutics* 3(12): 1505-1512 2004